WEBVTT

1
00:00:02.000 --> 00:00:06.122
What if the body's fullness signal could last longer?

2
00:00:06.122 --> 00:00:09.328
Cagrilintide takes the amylin story beyond pramlintide.

3
00:00:09.328 --> 00:00:13.450
It is one engineered peptide, not the two-medicine combination

4
00:00:13.450 --> 00:00:14.366
called CagriSema.

5
00:00:14.716 --> 00:00:18.497
Its development was reported in twenty twenty-one by Thomas

6
00:00:18.497 --> 00:00:22.278
Kruse and colleagues at Novo Nordisk in Måløv, Denmark.

7
00:00:22.278 --> 00:00:26.059
Their work changed the peptide and added a lipid

8
00:00:26.059 --> 00:00:29.840
side chain to support longer-lasting exposure, enabling once-weekly study.

9
00:00:30.190 --> 00:00:33.019
The biology is different from GLP-1.

10
00:00:33.019 --> 00:00:37.262
Amylin receptors combine a calcitonin receptor with an accessory

11
00:00:37.262 --> 00:00:41.505
protein. Cagrilintide activates amylin and calcitonin receptors, engaging pathways

12
00:00:41.505 --> 00:00:42.920
involved in fullness.

13
00:00:42.920 --> 00:00:47.163
A receptor signal is not a guarantee of a

14
00:00:47.163 --> 00:00:48.106
clinical result.

15
00:00:48.456 --> 00:00:52.502
Human evidence came from a twenty-six-week trial of seven

16
00:00:52.502 --> 00:00:56.548
hundred and six adults without diabetes, across fifty-seven sites

17
00:00:56.548 --> 00:00:57.896
in ten countries.

18
00:00:57.896 --> 00:01:01.942
Published in The Lancet in twenty twenty-one, it compared

19
00:01:01.942 --> 00:01:04.190
cagrilintide with placebo and liraglutide.

20
00:01:04.540 --> 00:01:08.112
Estimated average weight reduction ranged from six to ten

21
00:01:08.112 --> 00:01:11.685
point eight percent across cagrilintide groups, compared with three

22
00:01:11.685 --> 00:01:14.067
percent for placebo, assuming treatment adherence.

23
00:01:14.067 --> 00:01:17.640
These are group averages from a supervised trial, not

24
00:01:17.640 --> 00:01:19.228
predictions for an individual.

25
00:01:19.578 --> 00:01:24.382
Nausea, constipation, diarrhea and injection-site reactions were reported.

26
00:01:24.382 --> 00:01:29.786
In twenty twenty-five, researchers resolved receptor-bound structures, helping explain

27
00:01:29.786 --> 00:01:31.588
the molecular interactions.

28
00:01:31.588 --> 00:01:36.992
Structural insight does not replace long-term human safety evidence.

29
00:01:37.342 --> 00:01:41.576
The RENEW phase three programme now studies cagrilintide on

30
00:01:41.576 --> 00:01:45.811
its own. As of October thirteen, twenty twenty-six, this

31
00:01:45.811 --> 00:01:50.045
is an investigational development story, not a claim of

32
00:01:50.045 --> 00:01:54.279
worldwide approval. Next: CagriSema, two separate peptides working together.

33
00:01:55.000 --> 00:01:56.300
Peptides in 2.

34
00:01:56.300 --> 00:01:57.600
World Peptide Foundation.

35
00:01:57.820 --> 00:01:59.399
Every experience matters.